[FGFR-targeted therapy in head and neck carcinomas].
CONCLUSION: Early clinical and preclinical data point to the promise of biomarker-directed treatment of patients with head and neck tumors using FGFR-targeted TKIs.
PMID: 32519203 [PubMed - as supplied by publisher]
Source: HNO - Category: ENT & OMF Tags: HNO Source Type: research
More News: Adenocarcinoma | Cancer & Oncology | Carcinoma | Conferences | ENT & OMF | Genetics | HNSCC | Nutrition | Squamous Cell Carcinoma | Thyroid | Thyroid Cancer